This grant is to provide support for the Statistics and Data Management Center (SDMC) of the ECOG- ACRIN Cancer Research Group. The SDMC provides methodologic expertise, leadership, and support for the effective design and conduct of studies and collaborates in the management of NCTN. The Center has a streamlined leadership and organizational structure for its four offices located at the Department of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute (DFCI), the Department of Biostatistics, Center for Statistical Sciences at Brown University, the Frontier Science and Technology Research Foundation (FSTRF), and the American College of Radiology (ACR), under the direction of the Group Statisticians. The primary responsibility for data collection and management belongs to the Data Management Center, with offices in Boston (FSTRF) and Philadelphia (ACR). The primary responsibility for study design, monitoring, and analysis, and for overseeing and coordinating SDMC operations belongs to the Biostatistics Center, with offices in Boston (DFCI) and Providence (Brown University);The prime contact site for grant administration is DFCI.

Public Health Relevance

The primary goals of the SDMC are to provide methodologic expertise, leadership, and support in the design, development, implementation, and analysis of NCTN studies led by ECOG-ACRIN, to provide efficient and timely data collection and management of those studies, and to participate actively in all aspects of the collective management of the NCTN.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180794-01
Application #
8605248
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-29
Project End
2019-02-28
Budget Start
2014-04-29
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02215
Meropol, Neal J; Feng, Yang; Grem, Jean L et al. (2018) Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer 124:688-697
Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Kyriakopoulos, Christos E; Chen, Yu-Hui; Carducci, Michael A et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36:1080-1087
Zhao, Fengmin; Cella, David; Manola, Judith et al. (2018) Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. Support Care Cancer 26:1889-1895
Berlin, Jordan D; Feng, Yang; Catalano, Paul et al. (2018) An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). Oncology 94:39-46
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Swinnen, Lode J; O'Neill, Anne; Imus, Philip H et al. (2018) Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). Oncotarget 9:766-773
Estabrook, Ryne; Cella, David; Zhao, Fengmin et al. (2018) Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805. Qual Life Res 27:1589-1597
Harshman, Lauren C; Chen, Yu-Hui; Liu, Glenn et al. (2018) Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol 36:376-382

Showing the most recent 10 out of 187 publications